New analyses by international diabetes expertise provides strong support for the Diamyd® diabetes vaccine

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) informs that internationally leading researchers within the field of type 1 diabetes, independently of Diamyd Medical, has reanalyzed results from previous clinical studies with the Diamyd® diabetes vaccine using alternative statistical methods, termed Bayesian analysis. In an abstract submitted to a scientific meeting the authors conclude that the GAD-based diabetes vaccine Diamyd®, with very high probability preserves patients’ insulin producing capacity and that the continued development should aim to increase the efficacy.The